InnoCare Releases 2025 Interim Results and Business Highlights
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2025 interim results as of 30 June 2025.
August 20, 2025
by PharmaSources
InnoCare Releases 2024 Interim Results and Business Highlights
InnoCare Pharma announced the 2024 interim results and corporate update as of 30 June 2024.
August 21, 2024
InnoCare Pharma announced 2023 interim results as of 30 June 2023
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2023 interim results as of 30 June 2023.
September 4, 2023
by PharmaSources
Universal Medical Announces 2021 Interim Results
The board (the "Board") of directors (the "Directors") of Genertec Universal Medical Group Company Limited (the "Company" or "Universal Medical"; Stock code: 2666.HK) is pleased to announce the unaudited interim results of the Company and its subsidiaries
September 7, 2021
by ACN Newswire
CSPC Pharmaceutical Announces 2020 Interim Results
For the current period, the Group recorded a revenue of RMB12,590 million, an increase of 12.6% year-on-year, and profit attributable to shareholders of RMB2,314 million, an increase of 23.2% year-on-year.
August 26, 2020
by prnasia
Therapix Biosciences Announces Interim Results of Phase IIa Study for Obstructive Sleep Apnea
Therapix Biosciences announced interim results from its Phase IIa clinical study at Assuta Medical Center in Israel, suggesting that THX-110, a combination of dronabinol (∆-9-tetrahydracannabinol) and CannAmide™ (palmitoylethanolamide, or PEA) ...
June 20, 2019
by americanpharmaceuticalreview
WuXi Biologics Reports Robust 2018 Interim Results
WuXi Biologics announced its unaudited interim results for the six months ended June 30, 2018 today.
August 21, 2018
by en-cphi.cn